nVision Medical

nVision Medical — the private American company founded in 2009 which is engaged in technologies of treatment of female health. nVision developed the medical device for collecting of cages in fallopian (uterine) pipes, helping to diagnose ovarian cancer at an early stage.

History

2018: Boston Scientific purchased nVision Medical for $275 million

In April, 2018 the large producer of the medical equipment of Boston Scientific announced acquisition of nVision Medical. The cost of the transaction is up to $275 million.

Under the terms of the agreement, Boston Scientific will pay nVision Medical about $150 million from own means at once, and the remained $125 million will be transferred within four years. However, this amount can be lower as depends on achievement of the clinical and commercial indicators stated in the agreement. Contract details are not disclosed.

Boston Scientific purchased the developer of the equipment for diagnosis of ovarian cancer

It is known only that Boston Scientific and nVision will conduct the additional clinical trial devoted to collecting of cages in uterine tubes by means of the startup equipment to help women with the increased risk of development of ovarian cancer quicker to reveal ovarian cancer and to make decisions concerning treatment.

Boston Scientific speaks, ovarian cancer is the fifth in prevalence cause of death of women from oncological diseases, however by 2018 still there are no recommended screening tests for detection of this disease.

The executive vice president of Boston Scientific and the president of division of MedSurg Dave Pierce said that nVision devices have the short-term potential of sales in $500 million, and in the future turnover from implementation can reach $2 billion as this equipment is even more often used by gynecologists and helps the growing number of women.

According to Pierce, every year about 300 thousand women delete ovaries in many respects because of identification of suspicious educations or presence of the version of a gene of BRCA which increases the probability of development of cancer.

Purchase of nVision will begin to make for Boston Scientific profit in 2020, predict in the company.^[1]

Notes